RECURRENT CERVICAL CANCER
Clinical trials for RECURRENT CERVICAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CERVICAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT CERVICAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for women battling returned cervical cancer
Disease control Not yet recruitingThis study is testing a new combination of three drugs for women whose cervical cancer has returned after initial treatment. It is for patients whose cancer cells have a specific marker called HER2. The main goal is to see if this combination can shrink or control the cancer and …
Matched conditions: RECURRENT CERVICAL CANCER
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for cervical cancer when standard immunotherapy fails
Disease control Not yet recruitingThis study is for women whose advanced cervical cancer has gotten worse after treatment with a common type of immunotherapy (PD-1/PD-L1 drugs). Researchers want to see if a new combination of two immunotherapy drugs plus chemotherapy, with or without an anti-blood-vessel drug, ca…
Matched conditions: RECURRENT CERVICAL CANCER
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for women with Tough-to-Treat cervical cancer
Disease control Not yet recruitingThis study is for women whose cervical cancer has returned or spread after standard chemotherapy and immunotherapy. It will compare a new drug called SHR-A2102 against standard chemotherapy to see which helps patients live longer. The main goal is to see if the new drug improves …
Matched conditions: RECURRENT CERVICAL CANCER
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Feb 23, 2026 14:56 UTC